Gut Microbiome Disruption Following SARS-CoV-2: A Review

Elda Righi(Ospedale Santa Maria della Misericordia di Udine), Assunta Sartor(University of Udine), Concetta Sciammarella(Inserm), Elisa Gentilotti(University of Verona), Lorenza Lambertenghi(University of Verona), Evelina Tacconelli(University of Verona), Matteo Morra(University of Verona), Nina Auerbach(University of Verona), Ilaria Dalla Vecchia(University of Verona), Massimo Mirandola(University of Verona), Anna Górska(University of Verona)
Microorganisms
January 9, 2024
10.3390/microorganisms12010131
Cited by 19

Related Papers

European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)
|Clinical Microbiology and Infection|2021|1k
Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With <i>E coli</i> or <i>Klebsiella pneumoniae</i> Bloodstream Infection and Ceftriaxone Resistance
|JAMA|2018|761
The WHO Bacterial Priority Pathogens List 2024: a prioritisation study to guide research, development, and public health strategies against antimicrobial resistance
|The Lancet Infectious Diseases|2025|526
Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by<i>Klebsiella pneumoniae</i>Carbapenemase–producing<i>K. pneumoniae</i>
|Clinical Infectious Diseases|2018|351
Association Between Minimum Inhibitory Concentration, Beta-lactamase Genes and Mortality for Patients Treated With Piperacillin/Tazobactam or Meropenem From the MERINO Study
|Clinical Infectious Diseases|2020|155